Our technique has the potential of producing robust miniature axicons in glass at a low cost, which could be used in miniaturized imaging systems for biomedical imaging applications, such as optical coherence tomography, or OCT.
Imaging is more accurate, helps guide decisions and facilitates tailored therapy, especially in younger heart attack patients who more frequently have plaque erosion or non-atherosclerotic coronary artery disease.
We are very pleased with the outcomes of this study, which are the culmination of hard work by 47 physicians across 18 collaborating hospitals...What is further encouraging is that this study was undertaken without key technological improvements that have since been launched commercially. We anticipate that future studies using the Real-time Targeting laser marking feature and our newly launched artificial intelligence software, Intelligent Real-time Image Segmentation, will improve upon these already very positive results. Working together with our commercial partner, Merit Medical, and many of the leading hospitals in the United States, we are ecstatic that this technology continues to have an important and beneficial impact for patients.
We can’t use functional OCT/OCTA in the brain to look at neurovascular coupling at the cellular level because the brain is surrounded by the skull, and fine resolution isn’t possible...But we can use functional OCT/OCTA to examine the interactions between individual photoreceptors and their blood vessels in the retina, which is much more accessible in the eye.
With the NSTIN plot, the temporal quadrant of the retinal nerve fiber layer is displayed in the center of the B-scan. This portion of the disc is crucial for everyday visual function, and identification of abnormal thinning in this region is essential for managing glaucoma.
Conavi is delighted to receive approval for the clinical use of the Novasight Hybrid System in Canada and are thankful to the many researchers, clinicians, patients, employees and other stakeholders that made this milestone possible.
We are very excited and honored to partner with the team at Adachi. Adachi’s strong market presence in Otolaryngology, as well as their expertise in navigating Japanese regulatory and reimbursement pathways, will ensure a powerful launch of the TOMi Scope in the Japanese marketplace. We see this partnership as further validation of our technology and its potential to impact healthcare in a meaningful way. We look forward to a long and fruitful relationship with Adachi.
